ClinicalTrials.gg
TerminatedNCT05479058CAPYBARAUpdated Oct 4, 2024Results posted

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

A Phase 3 interventional study of Filgotinib and Placebo in Ulcerative Colitis, sponsored by Galapagos NV. Terminated at 50 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Galapagos NV · Phase 3, Interventional, and Treatment

Why this study was terminated
the planned number of participants needed to ensure adequate precision in the estimations and to draw meaningful conclusions was unlikely to be met, questioning the scientific value and ethical grounds for study continuation

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.

Enrollment
210th of 215
22 · median 196
Started
2022
with 12 others
Phase 3
83 of 221
13 open now
Registered
156th of 221
by date

Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 210th largest by enrollment of the 215 interventional ones that give a count, is one of 13 that started in 2022, is one of 83 in phase 3, and was the 156th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Colitis, Ulcerative with a site in Poland, or all of them as a file.
02

Study summary

Participants who were in clinical remission on 200 milligram (mg) filgotinib once daily for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), were planned to be rolled over and randomized in this study. The primary objective of this study was to evaluate the efficacy of filgotinib in participants in stable clinical remission on 200 mg filgotinib once daily for whom the dose was decreased to 100 mg once daily compared to participants remaining on 200 mg once daily.

Read the detailed description

Participants were planned to receive the blinded treatment until primary analysis time point. After unblinding at the study primary analysis time point, participants would have received unblinded treatment. The clinical trial was originally designed with the primary endpoint to be assessed at Week 48. Due to early termination of the study, none of the participants completed 48 weeks of treatment. All participants participated in blinded treatment period only and the study was unblinded globally after study completion.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have participated in the SELECTION-LTE study (GS-US-418-3899), who were on 200 mg filgotinib once daily and fulfilled the following conditions:

    • partial Mayo Clinical Score remission over a period of at least 2 consecutive quarterly visits in the SELECTION-LTE study (GS-US-418-3899) prior to screening of the present study;
    • free of for at least 12 weeks prior to and including baseline;
    • fecal calprotectin (FCP) ≤250 microgram per gram (μg/g) at last observation within 6 months prior to screening or FCP ≤250 μg/g during the screening of the present study.
    • sigmoidoscopy ES of 0 or 1 (local score) at screening.
  • Willing to refrain from during the study and for 12 weeks after the last dose of filgotinib in the study.
  • Female participants of must have had a negative highly sensitive (serum beta human chorionic gonadotropin) pregnancy test during screening and must have agreed to continued monthly urine dipstick pregnancy testing during filgotinib treatment.
  • Female participants of childbearing potential must have agreed to use highly effective measures as defined in the protocol.

Key Exclusion Criteria:

  • Any chronic medical condition (including but not limited to, cardiac or pulmonary disease, alcohol, or drug abuse) that, in the opinion of the investigator or sponsor, would make the participant unsuitable for the study or would prevent compliance with the study protocol.
  • Participant had a known to filgotinib ingredients or history of a significant allergic reaction to filgotinib ingredients as determined by the investigator.
  • Female participant who was pregnant or breastfeeding, or intended to become pregnant or breastfeed, and/or plans to undergo egg donation or egg harvesting for the purpose of current or future fertilization, during the study and until the end of the study.
  • Participant was unable or unwilling to comply with restrictions regarding prior and concomitant medication as described in the protocol.
  • Participant had a positive QuantiFERON® tuberculosis (TB) test at screening or had 2 indeterminate QuantiFERON® TB test results that required product (IP) treatment interruption, or participant had sign and symptoms of TB reactivation at screening.
  • History of during or in the last 5 years prior to participation in the UC parent studies, except for participants who had been successfully treated for nonmelanoma skin cancer or cervical carcinoma in situ.
  • Participant met discontinuation criteria of the SELECTION-LTE study (GS-US-418-3899).

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg

    Participants received filgotinib 200 mg and placebo to match filgotinib 100 mg once daily orally.

    Drug: Filgotinib · Drug: Placebo

  • Experimental
    Filgotinib 100 mg

    Participants received filgotinib 100 mg and placebo to match filgotinib 200 mg once daily orally.

    Drug: Filgotinib · Drug: Placebo

Interventions

  • Administered orally once daily

    Also known as: GS-6034, GLPG0634

  • DrugPlacebo

    Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Corticosteroid-free Clinical Remission Based on Modified Mayo Clinical Score (mMCS)

    The mMCS is a tool designed to measure disease activity for ulcerative colitis. The mMCS was calculated as the sum of the 3 subscores: stool frequency, rectal bleeding, and endoscopy. Each subscore was graded from 0 to 3 with higher scores indicating more severe disease activity. The total mMCS score ranged from 0 to 9 with higher scores indicating more severe disease activity. The mMCS remission was defined as a total score of score ≤2, with endoscopic subscore of ≤1, stool frequency subscore of ≤1, and a rectal bleeding subscore of 0. Corticosteroid-free mMCS remission was defined as being free of corticosteroids for at least 12 weeks.

    Time frame: Week 48

Secondary outcomes

  1. Time to Patient-Reported Outcome Based on 2 Items (PRO2) Flare

    PRO2 flare was defined as a PRO2 score worsening of at least 2 points and an absolute PRO2 score of at least 3, with stool frequency subscore ≥2, and rectal bleeding subscore ≥1. PRO2 included items of stool frequency and rectal bleeding. The range of each item score was 0 to 3 with higher scores indicating more severe disease.

    Time frame: Baseline up to Week 48

  2. Time to ES-Confirmed UC Flare

    An ES-confirmed UC flare was defined as an increase in rectal bleeding subscore by at least 1 point and an increase in stool frequency subscore by at least 2 points and an increase in endoscopic subscore by at least 1 point. Each subscore graded from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Baseline up to Week 48

  3. Change From Baseline in C-Reactive Protein (CRP)

    CRP is an acute-phase protein which provides an objective criterion of inflammatory activity.

    Time frame: Baseline, Week 4, Week 12, Week 24, Week 36, and Week 48

  4. Change From Baseline in Fecal Calprotectin (FCP)

    Fecal calprotectin, a very stable biomarker, was a 36 kilodalton calcium and zinc binding protein of S-100 protein family which was neutrophil derived. It represents 60% of cytosolic proteins in neutrophils and was a measurement of neutrophil migration to the gastrointestinal tract.

    Time frame: Baseline, Week 4, Week 12, Week 24, Week 36, and Week 48

  5. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score

    The IBDQ is disease-specific questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in participants with the Inflammatory Bowel Disease (IBD). It comprised of 32 questions divided into four health subscales: bowel symptoms (10 questions); systemic symptoms, including sleep disorders and fatigue (5 questions); emotional function such as depression, aggression, and irritation (12 questions); and social function, meaning the ability to participate in social activities and to work (5 questions). The IBDQ total score was calculated as the sum of the responses (each ranging from 1 \[severe problem\] to 7 \[normal health\]) to all 32 questions. Total IBDQ score ranged from 32 to 224 with a higher score indicating a better HRQoL.

    Time frame: Baseline, Week 48

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and TEAEs Leading to Treatment Discontinuation

    An adverse event (AE) was any untoward medical occurrence, new or worsening of any preexisting condition, in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with this treatment. A TEAE was defined as * An AE which had a start date equal to or after the date of the first administration of study drug in this study and no later than 30 days after last administration of study drug. * And was either a newly reported event, or a worsening of an existing event. Serious TEAE was defined as a TEAE that * Resulted in death and was life-threatening; * Required in-patient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly / birth defect; * Was medically significant.

    Time frame: Baseline up to Week 48

07

Results

Posted Oct 4, 2024
Limitations and caveats
This study was terminated as the planned number of participants needed to ensure adequate precision in the estimations and to draw meaningful conclusions was unlikely to be met, questioning the scientific value and ethical grounds for study continuation.

Participant flow

Participants who were in clinical remission with filgotinib 200 milligrams (mg) once daily for at least 2 consecutive quarterly visits in the ongoing long-term extension (LTE) SELECTION-LTE study (GS-US-418-3899; NCT02914535) and who met the eligibility criteria, were rolled over and randomized to this study. Participants were enrolled at study sites in Poland, France, Germany, the United States, Belgium, Republic of Korea, Spain, and the United Kingdom.

Participant flow — Overall Study
MilestoneFilgotinib 200 mgFilgotinib 100 mg
Started1111
Completed00
Not completed1111
Withdrew: Withdrawal by subject11
Withdrew: Study terminated by sponsor1010

Outcome measures

PrimaryPercentage of Participants in Corticosteroid-free Clinical Remission Based on Modified Mayo Clinical Score (mMCS)

The mMCS is a tool designed to measure disease activity for ulcerative colitis. The mMCS was calculated as the sum of the 3 subscores: stool frequency, rectal bleeding, and endoscopy. Each subscore was graded from 0 to 3 with higher scores indicating more severe disease activity. The total mMCS score ranged from 0 to 9 with higher scores indicating more severe disease activity. The mMCS remission was defined as a total score of score ≤2, with endoscopic subscore of ≤1, stool frequency subscore of ≤1, and a rectal bleeding subscore of 0. Corticosteroid-free mMCS remission was defined as being free of corticosteroids for at least 12 weeks.

Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryTime to Patient-Reported Outcome Based on 2 Items (PRO2) Flare

PRO2 flare was defined as a PRO2 score worsening of at least 2 points and an absolute PRO2 score of at least 3, with stool frequency subscore ≥2, and rectal bleeding subscore ≥1. PRO2 included items of stool frequency and rectal bleeding. The range of each item score was 0 to 3 with higher scores indicating more severe disease.

Time frame:
Baseline up to Week 48
Reported as:
Median · days
Time to Patient-Reported Outcome Based on 2 Items (PRO2) Flare
daysFilgotinib 200 mgFilgotinib 100 mg
Time to Patient-Reported Outcome Based on 2 Items (PRO2) FlareNA (NA to NA)NA (NA to NA)
SecondaryTime to ES-Confirmed UC Flare

An ES-confirmed UC flare was defined as an increase in rectal bleeding subscore by at least 1 point and an increase in stool frequency subscore by at least 2 points and an increase in endoscopic subscore by at least 1 point. Each subscore graded from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Baseline up to Week 48
Reported as:
Median · days
Time to ES-Confirmed UC Flare
daysFilgotinib 200 mgFilgotinib 100 mg
Time to ES-Confirmed UC FlareNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in C-Reactive Protein (CRP)

CRP is an acute-phase protein which provides an objective criterion of inflammatory activity.

Time frame:
Baseline, Week 4, Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · milligrams per liter (mg/L)
Change From Baseline in C-Reactive Protein (CRP)
milligrams per liter (mg/L)Filgotinib 200 mgFilgotinib 100 mg
Change at Week 40.166 ± 0.5331.713 ± 4.423
Change at Week 120.532 ± 1.12810.406 ± 26.944
Change at Week 240.156 ± 0.12816.002 ± 34.093
Change at Week 360.367 ± 0.1921.443 ± 0.525
SecondaryChange From Baseline in Fecal Calprotectin (FCP)

Fecal calprotectin, a very stable biomarker, was a 36 kilodalton calcium and zinc binding protein of S-100 protein family which was neutrophil derived. It represents 60% of cytosolic proteins in neutrophils and was a measurement of neutrophil migration to the gastrointestinal tract.

Time frame:
Baseline, Week 4, Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · milligrams per kilogram (mg/kg)
Change From Baseline in Fecal Calprotectin (FCP)
milligrams per kilogram (mg/kg)Filgotinib 200 mgFilgotinib 100 mg
Change at Week 4-27.6 ± 37.2142.5 ± 307.7
Change at Week 12-16.7 ± 48.1920.6 ± 1996.2
Change at Week 24-52.0 ± 54.6374.3 ± 674.8
Change at Week 36-46.5 ± 65.8-8.0 ± 70.4
SecondaryChange From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score

The IBDQ is disease-specific questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in participants with the Inflammatory Bowel Disease (IBD). It comprised of 32 questions divided into four health subscales: bowel symptoms (10 questions); systemic symptoms, including sleep disorders and fatigue (5 questions); emotional function such as depression, aggression, and irritation (12 questions); and social function, meaning the ability to participate in social activities and to work (5 questions). The IBDQ total score was calculated as the sum of the responses (each ranging from 1 \[severe problem\] to 7 \[normal health\]) to all 32 questions. Total IBDQ score ranged from 32 to 224 with a higher score indicating a better HRQoL.

Time frame:
Baseline, Week 48

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and TEAEs Leading to Treatment Discontinuation

An adverse event (AE) was any untoward medical occurrence, new or worsening of any preexisting condition, in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with this treatment. A TEAE was defined as * An AE which had a start date equal to or after the date of the first administration of study drug in this study and no later than 30 days after last administration of study drug. * And was either a newly reported event, or a worsening of an existing event. Serious TEAE was defined as a TEAE that * Resulted in death and was life-threatening; * Required in-patient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly / birth defect; * Was medically significant.

Time frame:
Baseline up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and TEAEs Leading to Treatment Discontinuation
ParticipantsFilgotinib 200 mgFilgotinib 100 mg
TEAEs66
Serious TEAEs00
TEAEs Leading to Treatment Discontinuation00

Adverse events

Collected over Baseline up to Week 48. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg0/11 (0%)0/11 (0%)6/11 (54.5%)
Filgotinib 100 mg0/11 (0%)0/11 (0%)6/11 (54.5%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventFilgotinib 200 mgFilgotinib 100 mg
Colitis ulcerativeGastrointestinal disorders0/112/11
DiarrhoeaGastrointestinal disorders0/112/11
VomitingGastrointestinal disorders0/112/11
PostmenopauseSocial circumstances0/81/6
GastroenteritisInfections and infestations1/111/11
Campylobacter infectionInfections and infestations0/111/11
ConjunctivitisInfections and infestations0/111/11
LaryngitisInfections and infestations1/110/11
NasopharyngitisInfections and infestations0/111/11
SinusitisInfections and infestations0/111/11

Baseline characteristics

Safety Analysis Set included all randomized participants who were administered study drug at least once.

Age, Continuous
Age, Continuous(years)Filgotinib 200 mgFilgotinib 100 mgTotal
Mean56.5 ± 8.558.3 ± 10.757.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mgFilgotinib 100 mgTotal
Female8614
Male358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Filgotinib 200 mgFilgotinib 100 mgTotal
Hispanic or Latino101
Not Hispanic or Latino101121
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Filgotinib 200 mgFilgotinib 100 mgTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101121
More than one race000
Unknown or Not Reported000
08

Study locations

50 sites
  • University of Miami
    Miami, Florida 33136, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Gastro Center of Maryland - Columbia
    Columbia, Maryland 21045, United States
  • Rapid City Medical Center
    Rapid City, South Dakota 57701, United States
  • Gastroenterology Associates of Tidewater
    Chesapeake, Virginia 23320, United States
  • Universitair Ziekenhuis Leuven Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hepato-Gastroenterology HK
    Hradec Králové, 500 12, Czechia
  • GEP Clinic
    Praha, 130 00, Czechia
  • CHU Amiens-Picardie
    Amiens, 80054, France
  • Centre Hospitalier Universitaire Hôpital Nord Service D'Hépato-Gastro-Entérologie
    Marseille, 13015, France
  • Centre Hospitalier Universitaire de Nantes Hôtel Dieu Service d'hépato-gastroentérologie
    Nantes, 44000, France
  • Hôpital Haut-Lévêque Service d'Hépato-Gastro-Entérologie et Nutrition
    Pessac, 33600, France
  • Centre Hospitalier Lyon Sud Service d'Hépato-Gastroentérologie
    Pierre-Bénite, 69495, France
  • Hôpital Pontchaillou
    Rennes, 35033, France
  • Hopital Nord - CHU de Saint-Etienne Service de Gastro-Entérologie
    Saint-Étienne, 42055, France
  • Centre Hospitalier Universitaire de Nancy - Hôpital de Brabois Service d'Hépato-gastroentérologie
    Vandœuvre-lès-Nancy, 54500, France
  • DRK KliniKlinik für Innere Medizin Schwerpunkt Gastroenterologieken Berlin Westend
    Berlin, 14050, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • EUGASTRO GmbH
    Leipzig, 04103, Germany
  • Klinikum Lüneburg
    Lüneburg, 21339, Germany
  • Gastroenterologische Gemeinschaftspraxis Minden
    Minden, 32423, Germany
  • Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet
    Budapest, 1097, Hungary
  • Bugát Pál Kórház
    Gyöngyös, 3200, Hungary
  • IRCCS de Bellis Unità Operativa Complessa Gastroenterologia II
    Castellana Grotte, 70013, Italy
  • Azienda Ospedaliero-Universitaria Mater Domini Unita Operativa Fisopatologia Digestiva
    Catanzaro, 88100, Italy
  • Azienda Ospedaliero-Universitaria Pisana U.O. Gastroentrologia Stabilimento di Cisanello
    Pisa, 56124, Italy
  • Istituto di Ricovero e Cura a Carattere Scientifico - Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Yeungnam University Medical Center
    Daegu, 42415, Korea, Republic of
  • Kyung Hee University Hospital
    Seoul, 02447, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Yonsei University Health System Severance Hospital Gastroenterology
    Seoul, 03722, Korea, Republic of
  • Przychodnia Vitamed NFZ
    Bydgoszcz, 85-079, Poland
  • Gabinet Endoskopii Przewodu Pokarmowego
    Kraków, 31-009, Poland
  • Krakowskie Centrum Medyczne
    Kraków, 31-501, Poland
  • Centrum Opieki Zdrowotnej Orkan-Med
    Ksawerów, 95-054, Poland
  • Gabinet Lekarski Dr. Hab. N. Med. Bartosz Korczowski
    Rzeszów, 35-302, Poland
  • Endoskopia Sopot
    Sopot, 81-756, Poland
  • Torunskiego Centrum Gastrologii I Endoskopii - Gastromed
    Toruń, 87-100, Poland
  • H-T. Centrum Medyczne Spółka z Ograniczoną Odpowiedzialnością
    Tychy, 43-100, Poland
  • Niepubliczny Zakład Opieki Zdrowotnej VIVAMED Jadwiga Miecz
    Warsaw, 03-580, Poland
  • Bodyclinic
    Warszawa, 03-712, Poland
  • Centrum Medyczne Oporów
    Wrocław, 52-416, Poland
  • Santa Familia - Centrum Badań Profilaktyki i Leczenia
    Łódź, 90-302, Poland
  • Mediclinic Panorama
    Cape Town, 7500, South Africa
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
  • National Taiwan University Hospital Center for Infection Control
    Taipei, 10002, Taiwan
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Norfolk and Norwich University Hospital
    Norwich, NR4 YUY, United Kingdom
  • Saint Helens and Knowsley Teaching Hospitals NHS Trust
    Prescot, L35 5DR, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Oct 2023, 14 months.

Results were first posted in Oct 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 29, 2022
StartActual
Jul 26, 2022
Primary completionActual
Oct 9, 2023
CompletionActual
Oct 9, 2023
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05479058
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Jul 26, 2022
Primary completion
Oct 9, 2023
Completion
Oct 9, 2023
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion